Delisting, Listing Rule Failure, or Listing Transfer

SEC Filing Summary: Mainz Biomed N.V. (QUCY)

Business Context and Reporting Period

This Form 8-K was filed by Mainz Biomed N.V. (referred to in metadata as Quantum Cyber N.V.) on March 20, 2026. The registrant is incorporated in The Netherlands with principal executive offices in Mainz, Germany. The company is an emerging growth company with ordinary shares (QUCY) listed on the Nasdaq Capital Market.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.

Material Changes

The primary material event is a notice of failure to satisfy a continued listing rule. The company's ordinary shares failed to maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days (February 5, 2026, to March 19, 2026), violating Nasdaq Listing Rule 5550(a)(2).

Guidance, Outlook, and Risks

  • Compliance Period: The company has been granted an initial 180-day compliance period ending September 16, 2026, to regain compliance.
  • Remediation Requirements: To cure the deficiency, the stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.
  • Secondary Compliance Option: If the initial period is unsuccessful, the company may qualify for an additional 180-day period if it meets all other initial listing standards (excluding bid price) and potentially effects a reverse stock split.
  • Risks: There is no assurance the company will be eligible for the additional cure period or that Nasdaq will grant continued listing. Failure to cure the deficiency could result in delisting.
  • Current Status: The notice has no immediate impact on trading; shares will continue to be listed and traded on Nasdaq pending compliance.

Investor Verification Checklist

  • Verify the current trading price of QUCY to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
  • Monitor for any announcements regarding a reverse stock split, which may be necessary to regain compliance.
  • Review the company's market value of publicly held shares to ensure it meets other Nasdaq initial listing standards required for a potential second compliance period.
  • Check for any subsequent correspondence from Nasdaq regarding the status of the compliance period or delisting proceedings.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.